{"filing":{"accession_number":"0001213900-26-088061","cik":"0001766140","ticker":"UNCY","company_name":"Unicycive Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"ea0301699-8k_unicycive.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026088061/ea0301699-8k_unicycive.htm"},"events":[{"id":27056,"run_id":24627,"accession_number":"0001213900-26-088061","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing Q2 2026 financial results for Unicycive Therapeutics. The filing explicitly states under Item 2.02 that the company \"issued a press release announcing its financial results for the second quarter ended June 30, 2026\" with the press release furnished as Exhibit 99.1. The exhibit contains detailed financial statements (balance sheet, income statement) and per-share metrics (net loss of $(0.06) per share), along with a business update regarding the company's lead drug candidate OLC. This is a material disclosure affecting investor assessment of the registrant's financial condition and operational progress.","company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28421,"accession_number":"0001213900-26-088061","item_number":"2.02","item_title":"Results of Operations and Financial Conditions.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Unicycive Therapeutics. The filing explicitly states under Item 2.02 that the company \"issued a press release announcing its financial results for the second quarter ended June 30, 2026\" with the press release furnished as Exhibit 99.1. The exhibit contains detailed financial statements (balance sheet, income statement) and per-share metrics (net loss of $(0.06) per share), along with a business update regarding the company's lead drug candidate OLC. This is a material disclosure affecting investor assessment of the registrant's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:04:39.985839+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28421,"accession_number":"0001213900-26-088061","item_number":"2.02","item_title":"Results of Operations and Financial Conditions.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Unicycive Therapeutics. The filing explicitly states under Item 2.02 that the company \"issued a press release announcing its financial results for the second quarter ended June 30, 2026\" with the press release furnished as Exhibit 99.1. The exhibit contains detailed financial statements (balance sheet, income statement) and per-share metrics (net loss of $(0.06) per share), along with a business update regarding the company's lead drug candidate OLC. This is a material disclosure affecting investor assessment of the registrant's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:04:39.985839+00:00","company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","filing_date":"2026-08-12"}]}